ERAS

Erasca, Inc.

• Seeking Alpha·3d ago

  Verastem: A Two-For-One Clinical Readout In October And A Commercial Launch

• TipRanks·3d ago

  Erasca participates in a conference call with JPMorgan

• Seeking Alpha·3d ago

  Erasca: Revolution's Approval Just Took Risk Out Of The Fast Follower

• Seeking Alpha·10/01 11:44

  These ten healthcare stocks posted the biggest one-month losses

• NASDAQ·09/25 19:20

  Notable Friday Option Activity: APP, ERAS, CRDO

• Simply Wall St·09/23 12:35

  Did Fiduciary Duty Probes Just Shift Erasca Stock's Investment Narrative?

• Seeking Alpha·09/17 14:10

  10 mid-cap healthcare stocks with the strongest momentum grades

• Seeking Alpha·09/17 13:45

  These mid-cap stocks have A+ momentum grades and over 100% YTD growth

• Dow Jones·09/17 11:30

  S&P 500 Futures Climb In Premarket Trading; Generac Holdings, UDR Lead

• Simply Wall St·09/16 22:21

  Erasca (ERAS) Dropped, So What Is Driving Attention Now?

• TipRanks·09/16 16:30

  Erasca’s ERAS-601 Trial Completion: What Early Cancer Data Could Mean for Investors

• Simply Wall St·09/11 03:30

  What Erasca Stock's Pipeline Data Update Means For Shareholders

• TipRanks·09/02 12:18

  J.P. Morgan Keeps Their Buy Rating on Erasca (ERAS)

• TipRanks·08/27 13:10

  Erasca price target raised to $33 from $25 at JPMorgan

• Simply Wall St·08/26 17:19

  Should FDA Fast Track for ERAS-0015’s Pan-RAS Glue Require Action From Erasca (ERAS) Investors?